[FOMX] Foamix Pharmaceuticals Ltd.

Overview

Type of security: Stock

Sector: Consumer Durables

Industry: Specialty Chemicals

Market Capitalization: 207.57 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 11.13 Change: 0.13 (1.18%)
Ext. hours: Change: 0 (0%)

chart FOMX

Refresh chart

Strongest Trends Summary For FOMX

FOMX is in the medium-term down -17% below S&P in 2 months and down -39% in 7 months. In the long-term down -41% below S&P in 2 years and down -72% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. Its lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. The company is also developing FMX101 to treat rosacea; and FDX104 to treat chemotherapy-induced rashes, as well as early-stage foam formulations of various drugs for the treatment of dermatological indications, including antibacterial drugs, antifungal drugs, corticosteroids, and immunomodulators. Foamix Pharmaceuticals Ltd. has development and license agreements Bayer AG, Merz Pharmaceuticals, LLC, Actavis plc, Prestium Pharma, Inc. and Arkin Holdings Ltd., and others. It has operations in the United States, Germany, and Israel. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Fundamental Ratios
Shares Outstanding30.66 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities250 K Cash From Investing Activities-31.18 M Cash From Operating Activities-1.91 M Gross Profit420 K
Net Profit-3.08 M Operating Profit-3.07 M Total Assets49.82 M Total Current Assets42.28 M
Total Current Liabilities3.29 M Total Debt540 K Total Liabilities3.66 M Total Revenue450 K
Technical Data
High 52 week6.96 Low 52 week3.33 Last close3.69 Last change1.37%
RSI39.51 Average true range0.18 Beta0.9 Volume52.12 K
Simple moving average 20 days-1.39% Simple moving average 50 days-2.46% Simple moving average 200 days-24.87%
Performance Data
Performance Week4.83% Performance Month-4.65% Performance Quart-16.7% Performance Half-35.94%
Performance Year-43.84% Performance Year-to-date2.79% Volatility daily2.22% Volatility weekly4.96%
Volatility monthly10.17% Volatility yearly35.23% Relative Volume159.06% Average Volume466.6 K
New High0.82% New Low

News

2019-03-08 08:00:00 | Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2019

2019-03-07 08:00:00 | Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne

2019-03-06 08:00:00 | Foamix Pharmaceuticals to Present at the Cowen & Company 39th Annual Health Care Conference

2019-03-01 14:01:35 | Edited Transcript of FOMX earnings conference call or presentation 1-Mar-19 1:30pm GMT

2019-02-28 16:01:00 | Foamix Reports Fiscal Year 2018 Financial Results and Provides Corporate Update

2019-02-27 11:50:04 | How Many Insiders Bought Foamix Pharmaceuticals Ltd. NASDAQ:FOMX Shares?

2019-02-27 08:00:00 | Foamix Announces Positive Results from Phase 3 Open-Label Safety Study Evaluating FMX103 Topical Minocycline Foam for Treatment up to One Year

2019-02-26 08:00:00 | Foamix -- with Late-Stage Candidates in Acne and Rosacea -- to Participate at American Academy of Dermatology Annual Meeting

2019-02-21 10:31:03 | Will Foamix FOMX Report Negative Earnings Next Week? What You Should Know

2019-02-14 08:00:00 | Foamix Pharmaceuticals Fourth Quarter Financial Results Conference Call & Webcast Scheduled for March 1

2019-01-23 08:00:00 | Foamix Announces Appointment of Sharon Barbari to Board of Directors

2019-01-22 11:38:35 | Are Foamix Pharmaceuticals Ltd.’s NASDAQ:FOMX Interest Costs Too High?

2018-12-21 07:00:00 | Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne

2018-12-16 22:16:18 | Is Foamix Pharmaceuticals Ltd FOMX A Good Stock To Buy?

2018-12-14 12:49:07 | Could Foamix Pharmaceuticals Ltd.’s NASDAQ:FOMX Investor Composition Influence The Stock Price?

2018-11-27 08:00:00 | Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer

2018-11-20 08:29:19 | The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings

2018-11-19 08:00:00 | Foamix Announces Appointment of Anthony Bruno to Board of Directors

2018-11-13 07:55:00 | Recent Analysis Shows WPX Energy, Verizon Communications, Innovative Industrial Properties, Foamix Pharmaceuticals, O2Micro International, and Investment Technology Group Market Influences — Renewed Outlook, Key Drivers of Growth

2018-11-08 21:17:00 | Edited Transcript of FOMX earnings conference call or presentation 8-Nov-18 1:30pm GMT

2018-11-07 19:50:12 | Foamix FOMX Reports Q3 Loss, Lags Revenue Estimates

2018-11-07 16:05:00 | Foamix Reports Third Quarter 2018 Financial Results and Provides Corporate Update

2018-11-07 06:00:01 | Foamix's treatment for common skin condition meets late-stage trial goals

2018-11-07 06:00:00 | Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea

2018-10-29 08:49:12 | Implied Volatility Surging for Foamix FOMX Stock Options

2018-10-29 08:00:00 | Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 8

2018-10-22 12:26:04 | Does Foamix Pharmaceuticals Ltd NASDAQ:FOMX Have A High Beta?

2018-10-12 08:00:00 | Foamix to Present Clinical Data From Study FX2017-22 at the Fall Clinical Dermatology Conference

2018-10-01 08:00:00 | Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial Study FX2017-22 Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne

2018-09-26 08:00:00 | Foamix Pharmaceuticals to Participate in the Cantor Fitzgerald Global Healthcare Conference

2018-09-18 10:55:04 | Foamix Announces Closing of its Follow-on Offering of Ordinary Shares and Full Exercise of its Option by the Underwriters

2018-09-13 19:06:02 | Foamix Announces Pricing of its Follow-on Offering of Ordinary Shares

2018-09-12 16:31:58 | Foamix Announces Proposed Follow-on Offering of Ordinary Shares

2018-09-12 14:15:00 | Cannabis and Biotech Stock that could Explode

2018-09-12 09:58:01 | Foamix's Acne Candidate Succeeds in Study, Shares Rally

2018-09-12 08:34:00 | Foamix stock surges 30% on positive late-stage results for acne medication

2018-09-12 08:30:00 | Foamix's stock rockets after successful trial results for acne treatment

2018-09-12 08:26:51 | The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt

2018-09-11 17:39:53 | Foamix acne drug meets main goals in late-stage trial, shares surge

2018-09-11 17:00:00 | Foamix Announces Positive Topline Results from Third Phase 3 Trial Study FX2017-22 Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne

2018-09-07 11:54:26 | Did An Insider Sell Their Shares In Foamix Pharmaceuticals Ltd NASDAQ:FOMX?

2018-08-21 08:39:12 | Implied Volatility Surging for Foamix Pharmaceuticals FOMX Stock Options

2018-08-08 19:40:11 | Foamix FOMX Reports Q2 Loss, Lags Revenue Estimates

2018-08-08 18:37:33 | Foamix: 2Q Earnings Snapshot

2018-08-08 16:01:00 | Foamix Reports Second Quarter 2018 Financial Results and Provides Corporate Update

2018-08-01 08:00:00 | Foamix Pharmaceuticals to Announce Second Quarter Financial Results on August 8

2018-06-27 09:04:56 | CORRECTING and REPLACING -- Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103

2018-06-14 08:00:00 | Foamix Pharmaceuticals to Participate in the Cantor Dermatology & Aesthetics Summit

2018-06-13 08:12:56 | Why Galmed Pharmaceuticals Stock Rose 151% on June 12

2018-05-22 12:02:17 | May Best Growth Stocks